IL133143A0 - Treatment of diabetes with rosiglitazone and insulin - Google Patents

Treatment of diabetes with rosiglitazone and insulin

Info

Publication number
IL133143A0
IL133143A0 IL13314398A IL13314398A IL133143A0 IL 133143 A0 IL133143 A0 IL 133143A0 IL 13314398 A IL13314398 A IL 13314398A IL 13314398 A IL13314398 A IL 13314398A IL 133143 A0 IL133143 A0 IL 133143A0
Authority
IL
Israel
Prior art keywords
rosiglitazone
insulin
diabetes
treatment
Prior art date
Application number
IL13314398A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133143A0 publication Critical patent/IL133143A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13314398A 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin IL133143A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
IL133143A0 true IL133143A0 (en) 2001-03-19

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13314398A IL133143A0 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (no)
JP (1) JP2002504138A (no)
KR (1) KR20010013843A (no)
CN (1) CN1133431C (no)
AP (1) AP1287A (no)
AR (2) AR012997A1 (no)
AU (1) AU8216398A (no)
BG (1) BG104059A (no)
BR (1) BR9810444A (no)
CA (1) CA2294141A1 (no)
CO (1) CO4940454A1 (no)
DZ (1) DZ2521A1 (no)
EA (1) EA004800B1 (no)
GB (1) GB9712866D0 (no)
HU (1) HUP0003260A3 (no)
ID (1) ID23951A (no)
IL (1) IL133143A0 (no)
IN (1) IN189723B (no)
MA (1) MA26511A1 (no)
NO (1) NO996265L (no)
OA (1) OA11517A (no)
PE (1) PE104499A1 (no)
PL (1) PL343123A1 (no)
SK (1) SK179399A3 (no)
TR (1) TR199903095T2 (no)
TW (1) TW587937B (no)
UA (1) UA70299C2 (no)
UY (1) UY25050A1 (no)
WO (1) WO1998057636A1 (no)
ZA (1) ZA985237B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (es) 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법

Also Published As

Publication number Publication date
TW587937B (en) 2004-05-21
CO4940454A1 (es) 2000-07-24
PL343123A1 (en) 2001-07-30
CN1260715A (zh) 2000-07-19
AU8216398A (en) 1999-01-04
SK179399A3 (en) 2000-11-07
EA004800B1 (ru) 2004-08-26
BR9810444A (pt) 2000-09-05
CA2294141A1 (en) 1998-12-23
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
NO996265D0 (no) 1999-12-17
ID23951A (id) 2000-06-08
NO996265L (no) 1999-12-17
UY25050A1 (es) 2000-09-29
BG104059A (en) 2000-10-31
WO1998057636A1 (en) 1998-12-23
IN189723B (no) 2003-04-19
OA11517A (en) 2004-02-04
HUP0003260A3 (en) 2001-12-28
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
HUP0003260A2 (hu) 2001-05-28
ZA985237B (en) 2000-02-17
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
GB9712866D0 (en) 1997-08-20
DZ2521A1 (fr) 2003-02-08
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
UA70299C2 (en) 2004-10-15
TR199903095T2 (xx) 2000-08-21
EA200000042A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
HUP9902706A3 (en) Syringe with electronic representation of parameters
PL342517A1 (en) Methods of treating diabetes employing peptidic insulin analoques
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
IL127219A0 (en) The use of insulin sensitivity enhancers for treatment of hyperuricemia and compositions containing insulin sensitivity enhancers for treating the same
AP2000001733A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and diguanide
EP0832204A4 (en) TREATMENT OF INSULIN RESISTANCE
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL134045A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1028200A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PL337577A1 (en) Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
AU2940895A (en) Use of insulin and igf-i
AU9106491A (en) Method of preventing and treating insulin dependent diabetes mellitus
ZA969435B (en) Treatment of diabetes with a glucokinase gene
HK1042253A1 (zh) 化合物及其用於治療糖尿病並發症的用途
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9618290D0 (en) Treatment of diabetes
IL94241A0 (en) Diagnosis and treatment of insulin dependent diabetes mellitus
IL121656A0 (en) Diagnosis prevention and treatment of diabetes